Sunday, February 17, 2013

Celgene gains SFDA approval for marketing Revlimid (lenalidomide) to treat multiple myeloma

Celgene Corporation was granted approval for Revlimid ® (lenalidomide) by the SFDA to treat multiple myeloma. The approval, which is the first for Celgene in China, includes an Import Drug License. Revlimid is indicated for use in combination with dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.


REVLIMID® is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, or MDS, associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalitie.

Revlimid Worldwide annual sales in 2011 was $3.2b



Enter your email address:


Delivered by FeedBurner